chronic
obstruct
pulmonari
diseas
copd
major
caus
morbid
mortal
current
therapi
confer
partial
benefit
either
incomplet
improv
airflow
limit
reduc
acut
exacerb
henc
new
therapi
desir
absenc
robust
earli
predictor
clinic
efficaci
potenti
success
novel
therapeut
agent
copd
entir
known
drug
enter
rel
larg
costli
clinic
trial
new
predict
model
human
new
studi
design
sought
allow
confirm
pharmacodynam
potenti
clinic
meaning
effect
earli
develop
review
focus
human
challeng
model
lipopolysaccharid
endotoxin
ozon
rhinoviru
earli
clinic
develop
phase
novel
therapeut
agent
treatment
reduct
exacerb
copd
global
initi
chronic
obstruct
lung
diseas
defin
chronic
obstruct
pulmonari
diseas
copd
common
prevent
treatabl
diseas
character
persist
airflow
limit
usual
progress
associ
enhanc
chronic
inflammatori
respons
airway
lung
noxiou
particl
gase
exacerb
comorbid
contribut
overal
sever
individu
patient
exacerb
associ
increas
airway
system
inflamm
lead
airway
wall
edema
sputum
plug
bronchoconstrict
copd
remain
major
global
health
econom
burden
expect
third
lead
caus
death
fifth
lead
caus
disabl
copd
account
billion
health
care
expenditur
unit
state
alon
billion
direct
health
care
expenditur
billion
indirect
morbid
cost
billion
indirect
mortal
cost
europ
copd
account
billion
euro
health
care
spend
year
pharmacolog
therapi
use
control
symptom
well
reduc
exacerb
improv
exercis
toler
ambulatori
copd
patient
current
treat
longact
bronchodil
inhal
corticosteroid
along
system
corticosteroid
exacerb
press
need
develop
novel
approach
treatment
copd
prevent
reduct
acut
exacerb
copd
exist
therapi
give
partial
benefit
either
incomplet
improv
airflow
limit
reduc
acut
exacerb
henc
need
newer
effect
therapi
evid
exist
medic
reduc
lung
function
declin
long
term
inconclus
torch
studi
investig
effect
combin
salmeterol
plu
fluticason
either
compon
alon
placebo
rate
postbronchodil
forc
expiratori
volum
second
fev
declin
investig
found
salmeterol
plu
fluticason
reduc
rate
fev
declin
mlyear
compar
placebo
despit
larg
studi
metaanalysi
conduct
soriano
et
al
conclud
inhal
corticosteroid
show
signific
improv
lung
function
declin
compar
placebo
month
howev
month
signific
differ
placebo
inhal
corticosteroid
treatment
one
main
challeng
develop
new
therapeut
agent
treatment
prevent
acut
exacerb
copd
potenti
success
entir
known
investig
therapi
enter
rel
larg
phase
ii
studi
assess
clinic
outcom
period
longer
articl
review
experiment
challeng
perform
rel
earli
drug
develop
treatment
copd
order
obtain
preliminari
signal
safeti
efficaci
human
challeng
model
repres
local
inflammatori
respons
caus
exacerb
copd
howev
import
note
model
reflect
actual
exacerb
milieu
model
chosen
model
success
use
date
copd
drug
develop
depend
dose
given
inhal
challeng
model
may
also
caus
local
system
inflamm
thu
make
ideal
assess
inflammatori
process
lung
exacerb
potenti
therapeut
benefit
novel
agent
mimic
local
inflammatori
respons
lung
exacerb
lipopolysaccharid
lp
macromolecular
cell
wall
surfac
antigen
gramneg
bacteria
made
three
compon
antigen
polysaccharid
side
chain
core
oligosaccharid
lipid
moieti
lp
extrem
biolog
activ
substanc
use
mani
year
preclin
clinic
research
due
role
activ
mani
transcript
factor
serum
lp
bind
lipidbind
protein
facilit
associ
lp
cell
membran
turn
facilit
transfer
lp
complex
figur
trigger
signal
cascad
macrophag
lineag
endotheli
cell
result
secret
proinflammatori
cytokin
nitric
oxid
activ
complement
coagul
system
contribut
characterist
featur
inflamm
excess
stimul
endotox
shock
monocyt
macrophag
lp
trigger
product
power
inflammatori
mediat
includ
cytokin
eg
interleukin
il
tumor
necrosi
factor
tnf
plateletactiv
factor
stimul
product
prostaglandin
leukotrien
addit
lp
activ
result
enhanc
macrophag
phagocyt
cytotox
activ
activ
altern
complement
pathway
factor
induc
histamin
releas
affect
neutrophil
chemotaxi
accumul
kinin
activ
releas
bradykinin
vasoact
peptid
caus
hypotens
releas
mediat
subsequ
system
respons
make
lp
power
research
tool
evalu
inflammatori
pathway
healthi
subject
inhal
endotoxin
show
system
pulmonari
inflammatori
respons
recruit
neutrophil
macrophag
lung
tissu
inhal
nebul
dose
lp
via
dosimet
healthi
volunt
lead
increas
temperatur
blood
creactiv
protein
crp
blood
sputum
neutrophil
blood
monocyt
lymphocyt
blood
sputum
proinflammatori
mediat
includ
myeloperoxidas
mpo
matrix
monocyt
chemotact
macrophag
inflammatori
bronchial
segment
instil
induc
earli
phase
respons
hour
result
statist
signific
increas
neutrophil
tnf
antagonist
granulocyt
colonystimul
factor
neutrophil
macrophag
monocyt
increas
hour
post
instil
intranas
lp
challeng
may
least
invas
best
toler
model
clinic
symptom
minim
howev
littl
data
publish
date
use
model
valid
intranas
model
need
perform
compar
lp
inhal
challeng
model
better
understand
relev
lpstrigger
nasal
inflamm
phenomena
occur
central
distal
airway
copd
mani
effect
exogen
lp
block
medic
one
studi
pretreat
oral
prednisolon
cilomilast
effect
local
lpsinduc
inflammatori
respons
lung
pretreat
prednisolon
alon
significantli
inhibit
lpsinduc
crp
respons
cilomilast
attenu
increas
crp
significantli
similarli
anoth
studi
subject
receiv
simvastatin
mg
demonstr
reduct
neutrophil
mpo
matrix
bronchoalveolar
lavag
fluid
balf
well
reduct
plasma
crp
versu
placebo
hohlfeld
et
al
use
lp
show
roflumilast
reduc
influx
total
cell
neutrophil
eosinophil
airway
healthi
subject
segment
challeng
endotoxin
statist
signific
import
rememb
inhal
lp
challeng
model
acut
neutrophil
inflamm
model
copd
model
use
understand
biolog
effect
compound
inhibit
lp
pathway
tabl
ozon
major
compon
urban
environment
air
pollut
form
tropospher
primari
precursor
pollut
presenc
light
cleav
sunlight
figur
epidemiolog
studi
level
associ
exacerb
asthma
copd
pneumonia
experiment
exposur
healthi
human
subject
known
elicit
revers
impair
lung
function
well
acut
proxim
airway
neutrophil
inflamm
increas
concentr
sever
cytokin
mediat
inflamm
within
airway
first
report
studi
inflammatori
effect
lowlevel
exposur
ppb
hour
healthi
volunt
statist
signific
increas
polymorphononuclear
neutrophil
prostaglandin
e
lactat
dehydrogenas
decreas
phagocytosi
via
complement
receptor
similar
recent
studi
lowlevel
exposur
ppb
hour
increas
airway
neutrophil
monocyt
dendrit
cell
well
modif
express
hladr
monocyt
anoth
studi
examin
whether
circul
play
role
inflammatori
respons
follow
inhal
exposur
volunt
underw
control
exposur
ppb
hour
clean
air
two
separ
occas
induc
sputum
collect
subject
expos
reveal
mark
neutrophilia
increas
express
airway
macrophag
monocyt
circul
level
also
predict
magnitud
airway
neutrophil
respons
follow
inhal
exposur
number
differ
class
therapeut
agent
studi
challeng
model
healthi
volunt
therapeut
class
includ
corticosteroid
administ
oral
inhal
nonsteroid
antiinflammatori
drug
recent
studi
investig
effect
cxc
chemokin
receptor
cxcr
antagonist
report
holz
et
al
conduct
doubleblind
doubledummi
placebocontrol
threeperiod
crossov
studi
eighteen
healthi
subject
shown
screen
produc
increas
sputum
neutrophil
respons
exposur
ppb
randomli
assign
receiv
altern
singl
oral
inhal
dose
fluticason
mg
mg
prednisolon
oral
placebo
least
week
apart
compar
placebo
pretreat
inhal
oral
corticosteroid
result
signific
reduct
sputum
neutrophil
respect
associ
statist
signific
reduct
sputum
mpo
inhal
corticosteroid
oral
steroid
compar
placebo
mean
reduct
sputum
level
inhal
corticosteroid
oral
corticosteroid
similar
result
obtain
studi
conduct
alexi
et
al
subject
receiv
fluticason
mg
mg
sputum
neutrophilia
significantli
reduc
respect
follow
inflammatori
marker
also
significantli
reduc
dosedepend
manner
subject
receiv
fluticason
hladr
sputum
monocyt
serum
clara
cell
protein
level
marker
pulmonari
damag
significantli
increas
posto
challeng
schelegl
et
al
pretreat
healthi
volunt
indomethacin
shown
significantli
reduc
induc
decrement
fev
forc
vital
capac
compar
drug
placebo
associ
reduct
subject
symptom
cough
short
breath
throat
tickl
indomethacin
treatment
suggest
cyclooxygenas
product
play
partial
role
subject
symptom
associ
exposur
hazucha
et
al
demonstr
similar
reduct
induc
decrement
fev
forc
vital
capac
follow
singledos
treatment
either
mg
mg
ibuprofen
compar
placebo
associ
reduc
posto
balf
level
prostaglandin
e
thromboxan
novel
select
oral
cxc
chemokin
receptor
antagonist
inhibit
neutrophil
activ
modul
neutrophil
traffick
anim
model
eighteen
healthi
respond
increas
sputum
neutrophil
underw
challeng
test
ppb
hour
intermitt
exercis
hour
last
treatment
dose
sputum
induc
hour
postchalleng
follow
treatment
challeng
result
statist
significantli
lower
sputum
neutrophil
count
ml
compar
prednisolon
ml
p
placebo
ml
p
compar
result
obtain
total
cell
count
percentag
sputum
neutrophil
myeloperoxidas
sputum
supernat
post
challeng
inhibit
neutrophilia
peripher
blood
significantli
less
sputum
gaga
studi
copd
conduct
use
concentr
rang
ppb
minut
exercis
everi
minut
aim
maintain
ventilatori
rate
lmin
studi
nine
subject
copd
ten
agematch
control
gong
et
al
found
increas
specif
airway
resist
statist
signific
decreas
fev
copd
subject
versu
agematch
control
summari
challeng
well
toler
healthi
volunt
older
subject
well
subject
asthma
copd
challeng
model
potenti
provid
critic
decisionmak
data
understand
whether
new
compound
desir
biolog
effect
healthi
volunt
patient
copd
henc
derisk
decis
move
forward
larg
phase
ii
safeti
efficaci
trial
rhinoviru
respons
common
cold
spread
infect
respiratori
secret
one
person
anoth
human
rhinoviru
hrv
replic
thu
link
upper
airway
infect
mucos
surfac
cooler
evid
exist
hrv
limit
upper
airway
gern
et
al
hrv
bind
intracellular
adhes
molecul
icam
major
hrv
receptor
lowdensitylipoprotein
receptor
bind
minor
group
hrv
gene
map
human
chromosom
gene
number
picornaviru
receptor
sever
studi
shown
induct
proinflammatori
gene
implic
neutrophil
activ
follow
rhinoviru
induct
bronchial
epitheli
cell
eg
regul
signal
pathway
rhinoviru
infect
epitheli
cell
lead
releas
proinflammatori
cytokin
chemokin
includ
chemokin
attract
inflammatori
cell
eg
neutrophil
eosinophil
cell
releas
toxic
product
stimul
mucu
product
lead
tissu
damag
possibl
longterm
loss
lung
function
mediat
direct
effect
caus
bronchoconstrict
vasoconstrict
result
airflow
obstruct
impair
ga
exchang
healthi
subject
subject
asthma
subject
allerg
asthma
intens
studi
clinic
trial
inocul
rhinoviru
rhinoviru
serotyp
studi
demonstr
rhinoviru
infect
lower
airway
common
experiment
inocul
sever
studi
look
caus
exacerb
copd
shown
virus
account
exacerb
hrv
numer
import
viru
type
figur
depict
total
viral
hrv
exacerb
rate
seven
exacerb
studi
virus
associ
acut
exacerb
copd
coronaviru
influenza
b
parainfluenza
adenoviru
respiratori
syncyti
viru
develop
model
viral
exacerb
subject
copd
mallia
et
al
conduct
viru
doseescal
studi
infect
four
copd
subject
rhinoviru
studi
median
tissu
cultur
infect
dose
rhinoviru
administ
inhal
rout
use
nebul
elicit
copd
exacerb
although
decreas
fev
peak
expiratori
flow
maxim
day
statist
signific
increas
total
sputum
cell
count
peripher
neutrophil
count
symptom
cold
lower
respiratori
tract
symptom
well
lung
function
chang
characterist
viralinduc
exacerb
copd
observ
increas
although
statist
signific
proinflammatori
cytokin
anoth
studi
signific
increas
total
respiratori
score
copd
subject
submit
manuscript
wwwdovepresscom
dovepress
dovepress
healthi
control
peak
expiratori
flow
fell
ml
control
p
signific
ml
p
copd
patient
peripher
white
cell
count
neutrophil
increas
group
sputum
neutrophil
count
also
increas
copd
patient
control
recent
upper
lower
symptom
score
found
significantli
higher
copd
subject
studi
ten
infect
copd
subject
met
criteria
defin
exacerb
copd
subject
copd
group
demonstr
signific
decreas
peak
expiratori
flow
baselin
control
group
blood
sputum
show
signific
increas
peripher
neutrophil
copd
subject
control
howev
crp
significantli
increas
group
day
subject
copd
group
significantli
increas
sputum
neutrophil
elastas
level
baselin
day
well
level
day
sputum
neutrophil
elastas
level
significantli
higher
subject
copd
compar
control
subject
day
date
one
laboratori
publish
model
data
interpret
caution
main
advantag
model
give
clear
understand
insight
molecular
cellular
inflammatori
process
take
place
viralassoci
exacerb
copd
publish
data
date
effect
pharmacolog
intervent
model
rhinoviru
challeng
model
potenti
use
preclin
clinic
tool
identifi
investig
novel
drug
target
establish
whether
new
therapeut
agent
potenti
clinic
util
includ
limit
target
solubl
thu
inhibit
interact
hrv
inhibitor
rhinoviru
rnadepend
rna
polymeras
activ
retino
acidinduc
gene
inhibitor
rhinoviru
capsid
protein
inhibitor
differ
rhinoviru
proteas
eg
current
model
reflect
underli
mechan
viral
exacerb
copd
use
challeng
model
potenti
significantli
inform
earli
decis
make
embark
longterm
phase
ii
iii
clinic
trial
design
test
intervent
may
treat
avert
exacerb
copd
although
challeng
model
good
predict
model
acut
exacerb
copd
ethic
consider
associ
induc
exacerb
subject
copd
therefor
safeti
board
may
advis
consid
subject
mild
copd
inclus
studi
healthi
subject
could
use
altern
determin
effect
development
drug
mechan
action
lung
inflamm
lp
model
use
success
healthi
subject
model
repres
local
inflamm
lung
exacerb
test
mechan
action
potenti
novel
drug
data
may
use
futur
decis
make
lp
challeng
model
best
valid
model
subject
copd
pharmaceut
compani
use
lp
model
mean
establish
proof
principl
earli
clinic
develop
process
rel
simpl
perform
advers
event
model
cost
effect
conduct
healthi
subject
easi
recruit
lp
challeng
data
whether
posit
neg
provid
valuabl
inform
aid
invest
decis
make
one
disadvantag
lp
model
model
lung
inflamm
diseas
state
thu
preclin
valid
development
drug
effect
lp
pathway
essenti
antiinflammatori
target
involv
tolllik
receptor
pathway
lp
challeng
model
model
choic
despit
longstand
knowledg
understand
advers
effect
pulmonari
biolog
use
challeng
model
assess
potenti
new
drug
prevent
acut
exacerb
copd
rel
new
model
shown
safe
side
effect
healthi
volunt
patient
asthma
copd
addit
reliabl
reproduc
use
success
gener
biolog
effect
system
effect
fluticason
antagonist
limit
model
yet
determin
whether
inhibit
neutrophilia
translat
clinic
benefit
patient
copd
preliminari
data
indic
inhibit
neutrophil
respons
follow
challeng
may
associ
benefici
chang
system
score
obtain
subject
copd
challeng
rhinoviru
elicit
mild
exacerb
subject
copd
appear
safe
well
toler
copd
subject
expos
model
observ
fev
alway
return
baselin
induc
exacerb
copd
subject
may
call
question
feasibl
use
challeng
broader
popul
patient
copd
addit
rais
ethic
consider
remain
excit
model
great
deal
potenti
rhinoviru
model
good
predict
model
viralinduc
acut
exacerb
copd
order
pharmaceut
compani
succeed
copd
arena
innov
approach
clinic
trial
design
conduct
requir
gener
critic
highqual
proof
efficaci
biolog
target
engag
data
support
earli
invest
decis
make
earli
drug
termin
facilit
betterinform
decis
regard
drug
proof
effect
clearli
demonstr
challeng
model
copd
expos
fewer
individu
short
period
time
elicit
agent
may
serv
surrog
potenti
efficaci
thu
may
help
earli
decis
make
reduct
clinic
develop
timelin
